- In 2024, agilon health reported that its eight REACH Accountable Care Organizations generated US$229 million in gross savings and achieved a 96% average quality score while managing care for about 121,000 Traditional Medicare beneficiaries under full-risk contracts.
- This combination of substantial cost savings for Medicare and consistently high quality scores offers a concrete data point on how agilon health’s value-based model can align physician incentives with better outcomes for seniors.
- We’ll now examine how this REACH ACO savings and quality performance reshapes agilon health’s investment narrative and future risk-reward profile.
Invest in the nuclear renaissance through our list of 89 elite nuclear energy infrastructure plays powering the global AI revolution.
agilon health Investment Narrative Recap
To be comfortable owning agilon health, you have to believe its value-based model can consistently turn clinical performance into sustainable economics, despite recent volatility in membership, margins, and leadership. The REACH ACO results are encouraging, but they do not directly resolve near term concerns around risk adjustment revenue, payer renegotiations for 2026, or cost trends in inpatient and oncology drugs, so their impact on the key short term catalyst and the biggest risk appears limited for now.
The REACH ACO announcement sits alongside agilon health’s recent 1-for-25 reverse stock split, executed in March 2026 to lift the share price and maintain NYSE listing. For investors tracking catalysts, that split, combined with the strong price move since, highlights how sensitive the stock can be to shifts in sentiment, even as underlying operational issues like medical margins and contracting economics remain central to the story.
Yet beneath the REACH savings headline, investors should be aware that...
Read the full narrative on agilon health (it's free!)
agilon health's narrative projects $7.0 billion revenue and $42.4 million earnings by 2029.
Uncover how agilon health's forecasts yield a $60.36 fair value, a 47% downside to its current price.
Exploring Other Perspectives
While the REACH savings highlight clinical success, the most pessimistic analysts were assuming only about 2.1 percent annual revenue growth and no profitability within three years, underscoring how sharply views on agilon health’s future can differ and why it is worth comparing multiple scenarios before deciding where you stand.
Explore 4 other fair value estimates on agilon health - why the stock might be a potential multi-bagger!
Decide For Yourself
Don't just follow the ticker - dig into the data and build a conviction that's truly your own.
- A great starting point for your agilon health research is our analysis highlighting 3 key rewards and 1 important warning sign that could impact your investment decision.
- Our free agilon health research report provides a comprehensive fundamental analysis summarized in a single visual - the Snowflake - making it easy to evaluate agilon health's overall financial health at a glance.
No Opportunity In agilon health?
Every day counts. These free picks are already gaining attention. See them before the crowd does:
- Capitalize on the AI infrastructure supercycle with our selection of the 52 best 'picks and shovels' of the AI gold rush converting record-breaking demand into massive cash flow.
- Uncover the next big thing with 20 elite penny stocks that balance risk and reward.
- Explore 26 top quantum computing companies leading the revolution in next-gen technology and shaping the future with breakthroughs in quantum algorithms, superconducting qubits, and cutting-edge research.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com